Precision Medicine Approaches in Alzheimer’s Disease: Clinical Perspective on ALZ-801

Authors

Keywords:

Alzheimer’s Disease, APOE4, ALZ-801, Valiltramiprosate, Amyloid-β Oligomers, Mild Cognitive Impairment, Hippocampal Atrophy, Cognitive Decline, Disease-Modifying Therapy, Neurodegeneration

Abstract

Background: Alzheimer's disease (AD) is a progressive neurodegenerative condition, resulting from abnormal protein accumulation in the brain. The global incidence is 9.8 million, as of 2021. The Apolipoprotein ε4 (APOE ε4) allele is a genetic factor that accelerates beta-amyloid buildup, consequently increasing the risk of early-onset AD in individuals with two copies of the allele. Valiltramiprosate/ALZ-801 is an oral drug that prevents neurotoxic Aβ oligomer formation, potentially serving as a disease modifying treatment. 

 

Objective-

The study aims to assess the efficacy and safety of ALZ-801 in AD, focusing on cognitive outcomes, functional performance, brain volume changes, adverse effects and APOE4 related responses.

 

Methodology- 

This study reviews APOLLOE4 trial findings evaluating the safety and efficacy of ALZ-801 in AD. Cognitive improvement was assessed by AD Assessment Scale-Cognitive Subscale (ADAS-Cog13) and Clinical Dementia Rating–Sum of Boxes [CDR-SB]. Diffuse tensor imaging of hippocampus and Amyloid-related imaging abnormalities (ARIA) was conducted along with Disability Assessment for Dementia (DAD).

 

Result- 

Treatment with ALZ-801 in early AD population showed 18% hippocampal atrophy slowing but no significant improvement in cognitive performance. However, the subgroup with mild cognitive impairment (MCI) demonstrated enhanced cognitive function, indicated by a 52% increase in scores on ADAS- Cog13 test. Functional assessments revealed 96% and 102% positive outcomes on DAD and CDR-SB scores, respectively suggesting improved functional abilities. The MCI group further demonstrated 26% reduction in hippocampal atrophy. Common side effects reported were nausea, vomiting and decreased appetite, with no increased risk of brain edema or hemorrhages.

 

Conclusion- 

Studies for ALZ-801 in early AD showed no notable clinical efficacy in the overall study population at 78 weeks. However, significant reduction in brain atrophy progression and functional decline was observed in the MCI subgroup. There was no evidence of increase in ARIA or serious adverse events, therefore supporting the drug’s safety and tolerability.

Downloads

Published

2026-08-19

How to Cite

Muraleedharan, T., & Balan, A. (2026). Precision Medicine Approaches in Alzheimer’s Disease: Clinical Perspective on ALZ-801. International Journal of Medical Students. Retrieved from https://ijms.pitt.edu/IJMS/article/view/4887

Issue

Forthcoming

Section

Abstracts of the WCMSR

Categories

License

Copyright (c) 2026 Tanishka Muraleedharan, Aditi Balan

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
    2. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
    3. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
    4. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
    5. The Author represents and warrants that:
      1. the Work is the Author’s original work;
      2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
      3. the Work is not pending review or under consideration by another publisher;
      4. the Work has not previously been published;
      5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
      6. the Work contains no libel, invasion of privacy, or other unlawful matter.
    6. The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.

Enforcement of copyright

The IJMS takes the protection of copyright very seriously.

If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.

If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to contact@ijms.org

 

Infringing material

If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to contact@ijms.org